161 related articles for article (PubMed ID: 33421199)
1. Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes.
Novitzky-Basso I; AlHayli S; Shin E; Pasic I; Al-Shaibani Z; Lam W; Law A; Michelis FV; Gerbitz A; Viswabandya A; Lipton JH; Kumar R; Mattsson J; Kim DDH
Eur J Haematol; 2021 Apr; 106(4):508-519. PubMed ID: 33421199
[TBL] [Abstract][Full Text] [Related]
2. Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD.
Moon JH; Hamad N; Sohn SK; Uhm J; Alam N; Gupta V; Lipton JH; Messner HA; Seftel M; Kuruvilla J; Kim DD
Ann Hematol; 2017 May; 96(5):805-815. PubMed ID: 28214979
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Cutaneous Disease Severity Estimates on Survival Outcomes in Patients With Chronic Graft-vs-Host Disease.
Baumrin E; Baker LX; Byrne M; Martin PJ; Flowers ME; Onstad L; El Jurdi N; Chen H; Beeghly-Fadiel A; Lee SJ; Tkaczyk ER
JAMA Dermatol; 2023 Apr; 159(4):393-402. PubMed ID: 36884224
[TBL] [Abstract][Full Text] [Related]
4. Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.
Kołodziejczak M; Gil L; de la Camara R; Styczyński J;
Ann Hematol; 2021 Mar; 100(3):763-777. PubMed ID: 33491135
[TBL] [Abstract][Full Text] [Related]
5. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
Saillard C; Crocchiolo R; Furst S; El-Cheikh J; Castagna L; Signori A; Oudin C; Faucher C; Lemarie C; Chabannon C; Granata A; Blaise D
Leuk Lymphoma; 2014 May; 55(5):1106-12. PubMed ID: 23822538
[TBL] [Abstract][Full Text] [Related]
6. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
[TBL] [Abstract][Full Text] [Related]
7. Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
Bhatt VR; Wang T; Chen K; Kitko CL; MacMillan ML; Pidala JA; Al Malki MM; Badawy SM; Beitinjaneh A; Ganguly S; Hamilton B; Hildebrandt GC; Lekakis LJ; Liu H; Maziarz RT; Modi D; Murthy HS; Preussler JM; Sharma A; Spellman SR; Arora M; Lee SJ
Transplant Cell Ther; 2022 Jan; 28(1):34-42. PubMed ID: 34637965
[TBL] [Abstract][Full Text] [Related]
8. Chronic liver graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients during tapering or after stopping calcineurin inhibitors.
Yoshimura K; Kimura SI; Kawamura M; Kawamura S; Takeshita J; Yoshino N; Misaki Y; Gomyo A; Matsumi S; Akahoshi Y; Tamaki M; Kusuda M; Kameda K; Wada H; Kawamura K; Sato M; Terasako-Saito K; Tanihara A; Nakasone H; Kako S; Kanda Y
Int J Hematol; 2021 Dec; 114(6):674-681. PubMed ID: 34378178
[TBL] [Abstract][Full Text] [Related]
9. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
[TBL] [Abstract][Full Text] [Related]
10. Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level.
Fingrut W; Law A; Lam W; Michelis FV; Viswabandya A; Lipton JH; Kumar R; Mattsson J; Kim DDH
Ann Hematol; 2021 Mar; 100(3):789-798. PubMed ID: 33415423
[TBL] [Abstract][Full Text] [Related]
11. The National Institutes of Health criteria for classification and scoring of chronic graft versus host disease: long-term follow-up of a single center series.
Tecchio C; Mosna F; Andreini A; Paoli L; Di Bella R; de Sabata D; Sorio M; Pizzolo G; Benedetti F
Leuk Lymphoma; 2013 May; 54(5):1020-7. PubMed ID: 23035648
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival.
Spina F; Radice T; De Philippis C; Soldarini M; Di Chio MC; Dodero A; Guidetti A; Viviani S; Corradini P
Leuk Lymphoma; 2019 Jan; 60(1):101-109. PubMed ID: 29716416
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
14. Combination of the Centre for International Blood and Marrow Transplant Registry Risk Score and the Global Severity Score Enhances Prognostic Risk Stratification in Patients Receiving Frontline Therapy for Chronic Graft-versus-Host Disease.
Shapiro RM; Shin E; Law AD; Lam W; Michelis FV; Viswabandya A; Kumar R; Lipton JH; Messner H; Mattsson J; Kim DDH
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1761-1769. PubMed ID: 31170520
[TBL] [Abstract][Full Text] [Related]
15. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.
Lee SJ; Klein JP; Barrett AJ; Ringden O; Antin JH; Cahn JY; Carabasi MH; Gale RP; Giralt S; Hale GA; Ilhan O; McCarthy PL; Socie G; Verdonck LF; Weisdorf DJ; Horowitz MM
Blood; 2002 Jul; 100(2):406-14. PubMed ID: 12091329
[TBL] [Abstract][Full Text] [Related]
16. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
[TBL] [Abstract][Full Text] [Related]
18. Age influences post-graft-versus-host disease non-relapse mortality in adults with acute graft-versus-host disease of varying severity following allogeneic hematopoietic cell transplant.
Nakane T; Fukuda T; Kanda J; Taniguchi S; Eto T; Ohashi K; Nakamae H; Kurokawa M; Mori T; Morishima Y; Nagamura-Inoue T; Sakamaki H; Atsuta Y; Murata M
Leuk Lymphoma; 2015; 56(8):2392-7. PubMed ID: 25629984
[TBL] [Abstract][Full Text] [Related]
19. National Institutes of Health-Defined Chronic Graft-vs.-Host Disease in Pediatric Hematopoietic Stem Cell Transplantation Patients Correlates With Parameters of Long-Term Immune Reconstitution.
Lawitschka A; Gueclue ED; Januszko A; Körmöczi U; Rottal A; Fritsch G; Bauer D; Peters C; Greinix HT; Pickl WF; Kuzmina Z
Front Immunol; 2019; 10():1879. PubMed ID: 31507582
[TBL] [Abstract][Full Text] [Related]
20. Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation.
Sohn SK; Kim DH; Baek JH; Kim JG; Lee KB; Lee KH; Lee JH; Choi SJ; Lee JH; Shin IH
Bone Marrow Transplant; 2006 Apr; 37(7):699-708. PubMed ID: 16501588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
